NCT06679413View on ClinicalTrials.gov

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Healthy Study Participants
Interventions
DRUG

midazolam

Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study

DRUG

metformin

Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study

DRUG

bupropion

Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study

DRUG

fenfluramine HCl

Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study

Trial Locations (1)

21225

Up0132 1001, Baltimore

All Listed Sponsors
lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT06679413 - A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants | Biotech Hunter | Biotech Hunter